Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis

Urol Int. 2011;87(2):159-64. doi: 10.1159/000329069. Epub 2011 May 28.

Abstract

Objectives: To examine the association between fibroblast growth factor receptor-4 (FGFR-4) genetic polymorphisms (Gly-388Arg) and prostate cancer susceptibility.

Methods: A comprehensive search was conducted to identify all case-control studies of FGFR-4 polymorphisms and prostate cancer risk. Statistical analysis was performed with the software program Stata, version 8.0, and Review Manage, version 4.2.

Results: A total of 4 eligible studies, including 2,618 cases and 2,305 controls, relating the FGFR-4 polymorphism to the risk of prostate cancer were identified. The overall results indicated a significant association between FGFR-4 polymorphisms and prostate cancer. In the subgroup analysis by ethnicity, a significant association was found between European descent for recessive model (random effects OR 0.82, 95% CI 0.72-0.93) and co-dominant genetic model (random effects OR 0.83, 95% CI 0.68-1.00). Sensitivity analysis also found a significant association in the recessive (random effects OR 0.68, 95% CI 0.49-0.95) or the co-dominant (random effects OR 0.68, 95% CI 0.49-0.96) models. Egger's test showed that publication bias was not present in any of the comparisons.

Conclusions: Gly-388Arg polymorphism of FGFR-4 most likely contributes to susceptibility to prostate cancer, especially in men of European descent.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Europe
  • Gene Expression Regulation, Neoplastic*
  • Genes, Dominant
  • Genes, Recessive
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Models, Genetic
  • Polymorphism, Genetic*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / metabolism*
  • Receptor, Fibroblast Growth Factor, Type 4 / genetics*
  • Receptor, Fibroblast Growth Factor, Type 4 / metabolism*
  • Risk
  • Sensitivity and Specificity

Substances

  • Receptor, Fibroblast Growth Factor, Type 4